If heritable retinoblastoma patients are treated systematically with a PARP inhibitor, the MMEJ pathway might also be inhibited in the non-cancerous cells, which would lead to potentially serious side effects, including synthetic lethality in these non-cancerous cells. This evidence concerns the gene PARP1 and retinoblastoma.